Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus PIROXICAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus PIROXICAM.
COXANTO vs PIROXICAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
1 g intravenous every 6 hours.
10-20 mg orally once daily; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
Clinical Note
moderatePiroxicam + Gatifloxacin
"Piroxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePiroxicam + Rosoxacin
"Piroxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePiroxicam + Levofloxacin
"Piroxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePiroxicam + Trovafloxacin
"Piroxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 50 hours (range 30-86 hours), allowing once-daily dosing. Prolonged in elderly (up to 80 hours) and in hepatic impairment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 60-70% renal (glomerular filtration and tubular secretion) as unchanged drug and metabolites; 30-40% fecal via biliary excretion. Less than 5% as unchanged drug in urine.
Category C
Category D/X
NSAID
NSAID